The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Change to ADS ratio

30 Oct 2019 10:31

RNS Number : 6279R
Tiziana Life Sciences PLC
30 October 2019
 

Tiziana Life Sciences plc

Change to ADS ratio

London, 30 October 2019 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA), announces a ratio change to its sponsored Level I American Depositary Receipt ("ADR") programme.

The former ratio of ten (10) ordinary shares to one (1) American Depositary Share ("ADS") has been changed to five (5) ordinary shares per one (1) ADS effective on 29 October 2019. There will be no change to the underlying ordinary shares.

ADR record date:

21 October 2019

ADR payment date:

28 October 2019

ADR effective date:

29 October 2019

Symbol:

TLSA

Traded:

NASDAQ

CUSIP:

88875G101

Old Ratio:

1 ADR: 10 ordinary Shares

New Ratio:

1 ADR: 5 ordinary Shares

Underlying ISIN:

GB00BKWNZY55

Country of incorporation:

United Kingdom

Depositary:

J.P. Morgan Chase Bank, N.A.

Custodian:

J.P. Morgan Chase Bank, London

 

To effect this change, ADR holders will receive one (1) additional ADR for every one (1) ADR held as of 21 October 2019, the ADR record date. Existing ADRs will continue to be valid and will not have to be exchanged for new ADRs. In connection with this change, the register held by JPMorgan has been closed for issuances and cancellations from the close of business 21 October 2019 and will reopen on 31 October 2019.

For further information, please contact:

JPMorgan Service Centre ADR Settlements

001 800-990-1135 001 302-552-0230

 

Contacts:

 

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder

+44 (0)20 7495 2379

Cairn Financial Advisers LLP (Nominated adviser)

Liam Murray / Jo Turner

+44 (0)20 7213 0883

Shore Capital (Nominated brokers)

Antonio Bossi

+44 (0)20 7408 4050

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAEEEDASNFFF
Date   Source Headline
20th Oct 20212:29 pmRNSScheme of arrangement
20th Oct 20212:00 pmRNSPrice Monitoring Extension
20th Oct 20217:00 amRNSDirector/PDMR Shareholding
19th Oct 20212:01 pmRNSCapital Reorganisation
6th Oct 20213:19 pmRNSDirector/PDMR Shareholding
5th Oct 20217:00 amRNSDirector/PDMR Dealing
4th Oct 20218:06 amRNSPDMR Dealing
28th Sep 20217:00 amRNSDirector/PDMR Shareholding
27th Sep 20215:16 pmRNSResult of Meeting
27th Sep 20215:11 pmRNSResult of Meeting
24th Sep 20215:49 pmRNSHalf-year Report
20th Sep 202111:05 amRNSSecond Price Monitoring Extn
20th Sep 202111:00 amRNSPrice Monitoring Extension
20th Sep 20219:05 amRNSSecond Price Monitoring Extn
20th Sep 20219:00 amRNSPrice Monitoring Extension
7th Sep 20216:00 pmRNSChange of Registered Office
7th Sep 20217:00 amRNSTLSA to Host Call to Discuss Exclusive License
3rd Sep 20215:00 pmRNSPosting of Scheme Document and Notice of Meetings
3rd Sep 20217:00 amRNSPosting of Scheme Document and Notice of Meetings
2nd Sep 202111:05 amRNSSecond Price Monitoring Extn
2nd Sep 202111:00 amRNSPrice Monitoring Extension
2nd Sep 20217:00 amRNSLicense Agreement to Evaluate Foralumab with CAR T
20th Aug 20217:00 amRNSTiLS files scheme for a corporate reorganisation
17th Aug 20217:00 amRNSArticle Publication on Foralumab in COVID Patients
16th Aug 20216:11 pmRNSTLSA to Present at the Q3 Virtual Investor Summit
3rd Aug 20214:41 pmRNSSecond Price Monitoring Extn
3rd Aug 20214:35 pmRNSPrice Monitoring Extension
8th Jul 202112:19 pmRNSADS Ex-Dividend Date Scheduled for July, 09 2021
2nd Jul 202112:30 pmRNSDistribution Dates for shares and ADRs in Accustem
2nd Jul 202112:30 pmRNSDistribution Dates: shares and ADRs in Accustem
30th Jun 202111:36 amRNSDr Howard Weiner on Bloomberg at 1.50pm ET today
25th Jun 202110:40 amRNSResult of Annual General Meeting
23rd Jun 20217:00 amRNSP2 Trial with foralumab on Severe COVID19 Patients
21st Jun 20217:08 amRNSAppointment of VP of Regulatory Affairs
17th Jun 20217:00 amRNSTiziana Applies for Grant from UK-CTAP
2nd Jun 20217:00 amRNSNotice of AGM
26th May 20217:00 amRNSSignificant Immunomodulation effects on Biomarkers
25th May 20217:00 amRNSTrial Initiation in a SPMS Patient with Foralumab
21st May 20217:00 amRNSDirector/PDMR Dealing
18th May 202112:18 pmRNSAmended - Final Results
18th May 202111:08 amRNSFinal Results
7th May 20217:00 amRNSTLSA interview on Bloomberg TV on 8th May 2021
5th May 20217:45 amRNSTLSA Strategic Initiative with Takanawa Japan K.K.
27th Apr 20217:00 amRNSB. Riley Virtual Neuroscience Investor Conference
13th Apr 202112:00 pmRNSTiziana Announces Plans to List Accustem in US
30th Mar 20214:41 pmRNSSecond Price Monitoring Extn
30th Mar 20214:36 pmRNSPrice Monitoring Extension
30th Mar 20212:05 pmRNSSecond Price Monitoring Extn
30th Mar 20212:00 pmRNSPrice Monitoring Extension
30th Mar 20211:00 pmRNSFDA Allows Foralumab Treatment for a SPMS Patient

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.